Comparative kinetics and dynamics of zaleplon, zolpidem, and placebo

Clinical Pharmacology and Therapeutics

Volumn 64, Issue 5, 1998, Pages 553-561

  Greenblatt, David J ^a   Harmatz, Jerold S ^b   Von Moltke, Lisa L ^b   Ehrenberg, Bruce L ^b   Harrel, Lisa ^b   Corbett, Kate ^b   Counihan, Molly ^b   Graf, Jennifer A ^b   Darwish, Mona ^b   Mertzanis, Polyxane ^b   Martin, Patrick T ^b   Cevallos, William H ^b   Shader, Richard I ^b  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ZALEPLON; ZOLPIDEM; ZOLPIDEM TARTRATE;

AMNESIA; AREA UNDER THE CURVE; ARTICLE; BETA RHYTHM; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENCY; DRUG STRUCTURE; HUMAN; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SEDATION; TASK PERFORMANCE;

EID: 13144254260     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(98)90139-4     Document Type: Article

References (27)

1. Vanover KE, Mangano RM, Barrett JE. CL 284,846, a novel sedative-hypnotic: evaluation of its metabolites for pharmacological activity in vitro and in vivo. Drug Devel Res 1994;33:39-45.
2. Vanover KE, Barrett JE. Evaluation of the discriminative stimulus effects of the novel sedative-hypnotic CL 284,846. Psychopharmacology (Berl) 1994;115:289-96.
3. Gaudreault J, Varin F, Pollack GM. Pharmacokinetics and anticonvulsant effect of a new hypnotic, CL 284,846, in rats. Pharmaceut Res 1995;12:1592-7.
4. Beer B, Ieni JR, Wu WH, Clody D, Amorusi P, Rose J, et al. A placebo-controlled evaluation of single, escalating doses of CL 284,846, a non-benzodiazepine hypnotic. J Clin Pharmacol 1994;34:335-44.
5. Allen D, Curran HV, Lader M. The effects of single-doses of CL 284,846, lorazepam, and placebo on psychomotor and memory function in normal male volunteers. Eur J Clin Pharmacol 1993;45:313-20.
6. Hoehns JD, Perry PJ. Zolpidem: a nonbenzodiazepine hypnotic for treatment of insomnia. Clin Pharm 1993;12:814-28.
7. Langtry HD, Benfield P. Zolpidem: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential. Drugs 1990;40:291-313.
8. Sanger DJ, Morel E, Perrault G. Comparison of the pharmacological profiles of the hypnotic drugs, zaleplon and zolpidem. Eur J Pharmacol 1996;313:35-42.
9. Greenblatt DJ, Ehrenberg BL, Gunderman J, Locniskar A, Scavone JM, Harmatz JS, et al. Pharmacokinetic and electroencephalographic study of intravenous diazepam, midazolam, and placebo. Clin Pharmacol Ther 1989; 45:356-65.
10. Greenblatt DJ, Ehrenberg BL, Gunderman J, Scavone JM, Tai NT, Harmatz JS, et al. Kinetic and dynamic study of intravenous lorazepam: comparison with intravenous diazepam. J Pharmacol Exp Ther 1989;250:134-40.
11. Greenblatt DJ, Harmatz JS, Gouthro TA, Locke J, Shader RI. Distinguishing a benzodiazepine agonist (triazolam) from a non-agonist anxiolytic (buspirone) by electroencephalography: kinetic-dynamic studies. Clin Pharmacol Ther 1994;56:100-11.
12. Friedman H, Greenblatt DJ, Peters GR, Metzler CM, Charlton MD, Harmatz JS, et al. Pharmacokinetics and pharmacodynamics of oral diazepam: effect of dose, plasma concentration, and time. Clin Pharmacol Ther 1992;52:139-50.
13. Laurijssens BE, Greenblatt DJ. Pharmacokinetic-pharmacodynamic relationships for benzodiazepines. Clin Pharmacokinet 1996;30:52-76.
14. Greenblatt DJ, Harmatz JS, Dorsey C, Shader RI. Comparative single-dose kinetics and dynamics of lorazepam, alprazolam, prazepam, and placebo. Clin Pharmacol Ther 1988;44:326-34.
15. Greenblatt DJ, Harmatz JS, Engelhardt N, Shader RI. Pharmacokinetic determinants of dynamic differences among three benzodiazepine hypnotics: flurazepam, temazepam, and triazolam. Arch Gen Psychiatry 1989;46:326-32.
16. Greenblatt DJ, Harmatz JS, Shapiro L, Engelhardt N, Gouthro TA, Shader RI. Sensitivity to triazolam in the elderly. N Engl J Med 1991;324:1691-8.
17. Lapierre KA, Greenblatt DJ, Goddard JE, Harmatz JS, Shader RI. The neuropsychiatric effects of aspartame in normal volunteers. J Clin Pharmacol 1990;30:454-60.
18. Kaplan GB, Greenblatt DJ, Ehrenberg BL, Goddard JE, Cotreau MM, Harmatz JS, et al. Dose-dependent pharmacokinetics and psychomotor effects of caffeine in humans. J Clin Pharmacol 1997;37:693-703.
19. Shader RI, Dreyfuss D, Gerrein JR, Harmatz JS, Allison SJ, Greenblatt DJ. Sedative effects and impaired learning and recall following single oral doses of lorazepam. Clin Pharmacol Ther 1986;39:526-9.
20. Greenblatt DJ, Harmatz JS. Kinetic-dynamic modeling in clinical psychopharmacology. J Clin Psychopharmacol 1993;13:231-4.
21. Fry J, Scharf MB, Berkowitz DV, Brown DW, Claghorn J, Ferguson J. et al. A phase III, 28 day, multicenter, double-blind comparator- and placebo-controlled, parallel-group safety, tolerability, and efficacy study of 5, 10, and 20 mg of zaleplon compared with 10 mg of zolpidem or placebo, in adult outpatients with insomnia [abstract]. Sleep 1998;21(suppl):262.
22. Vogel G, Erwin CW, Roth T, Zammit G, Whitaker T, Fujimori M, et al. Effects of a single dose of zaleplon on transient insomnia. Presented at the Twenty-first CINP Congress, Glasgow, Scotland, July 15, 1998.
23. Renwick AB, Mistry H, Ball SE, Walters DG, Kao J, Lake BG. Metabolism of zaleplon by human hepatic microsomal cytochrome P450 isoforms. Xenobiotica 1998;28: 337-48.
24. Salvà P, Costa J. Clinical pharmacokinetics and pharmacodynamics of zolpidem: therapeutic implications. Clin Pharmacokinet 1995;29:142-53.
25. Durand A, Thénot JP, Bianchetti G Morselli PL. Comparative pharmacokinetic profile of two imidazopyridine drugs: zolpidem and alpidem. Drug Metab Rev 1992; 24:239-66.
26. Patat A, Trocherie S, Thebault JJ, Rosenzweig P, Dubruc C. Bianchetti G, et al. EEG profile of intravenous zolpidem in healthy volunteers. Psychopharmacology (Berl) 1994;114:138-46.
27. Pichard L, Gillet G, Bonfils C, Domergue J, Thénot JP, Maurel P. Oxidative metabolism of zolpidem by human liver Cytochrome P450s. Drug Metab Dispos 1995; 23:1253-62.